A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers

Sadia Mahboob, Seong Beom Ahn, Harish R. Cheruku, David Cantor, Emma Rennel, Simon Fredriksson, Gabriella Edfeldt, Edmond J. Breen, Alamgir Khan, Abidali Mohamedali, Md Golam Muktadir, Shoba Ranganathan, Sock Hwee Tan, Edouard Nice, Mark S. Baker

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 μL) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek® Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay. Results: Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research. Proseek found that expression of Carcinoembryonic Antigen (CEA), IL-8 and prolactin are significantly correlated with CRC stage. Conclusions: CEA, IL-8 and prolactin expression were found to identify between control (unaffected), non-malignant (Dukes' A + B) and malignant (Dukes' C + D) stages.

LanguageEnglish
Article number10
Pages1-12
Number of pages12
JournalClinical Proteomics
Volume12
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Carcinoembryonic Antigen
Interleukin-8
Immunoassay
Prolactin
Colorectal Neoplasms
Plasmas
Biomarkers
Assays
Tumor Biomarkers
Early Detection of Cancer
Neoplasms
Proteins
Oncology
Edetic Acid
Proteomics
Tumors
Early Diagnosis
Screening
Tissue
Cytokines

Bibliographical note

Copyright the Author(s) 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Cite this

Mahboob, Sadia ; Ahn, Seong Beom ; Cheruku, Harish R. ; Cantor, David ; Rennel, Emma ; Fredriksson, Simon ; Edfeldt, Gabriella ; Breen, Edmond J. ; Khan, Alamgir ; Mohamedali, Abidali ; Muktadir, Md Golam ; Ranganathan, Shoba ; Tan, Sock Hwee ; Nice, Edouard ; Baker, Mark S. / A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers. In: Clinical Proteomics. 2015 ; Vol. 12, No. 1. pp. 1-12.
@article{52f25ccd08e84a49a7807fcb2e3f8b50,
title = "A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers",
abstract = "Background: Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 μL) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek{\circledR} Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay. Results: Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research. Proseek found that expression of Carcinoembryonic Antigen (CEA), IL-8 and prolactin are significantly correlated with CRC stage. Conclusions: CEA, IL-8 and prolactin expression were found to identify between control (unaffected), non-malignant (Dukes' A + B) and malignant (Dukes' C + D) stages.",
author = "Sadia Mahboob and Ahn, {Seong Beom} and Cheruku, {Harish R.} and David Cantor and Emma Rennel and Simon Fredriksson and Gabriella Edfeldt and Breen, {Edmond J.} and Alamgir Khan and Abidali Mohamedali and Muktadir, {Md Golam} and Shoba Ranganathan and Tan, {Sock Hwee} and Edouard Nice and Baker, {Mark S.}",
note = "Copyright the Author(s) 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2015",
doi = "10.1186/s12014-015-9081-x",
language = "English",
volume = "12",
pages = "1--12",
journal = "Clinical Proteomics",
issn = "1542-6416",
publisher = "Springer, Springer Nature",
number = "1",

}

A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers. / Mahboob, Sadia; Ahn, Seong Beom; Cheruku, Harish R.; Cantor, David; Rennel, Emma; Fredriksson, Simon; Edfeldt, Gabriella; Breen, Edmond J.; Khan, Alamgir; Mohamedali, Abidali; Muktadir, Md Golam; Ranganathan, Shoba; Tan, Sock Hwee; Nice, Edouard; Baker, Mark S.

In: Clinical Proteomics, Vol. 12, No. 1, 10, 2015, p. 1-12.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers

AU - Mahboob, Sadia

AU - Ahn, Seong Beom

AU - Cheruku, Harish R.

AU - Cantor, David

AU - Rennel, Emma

AU - Fredriksson, Simon

AU - Edfeldt, Gabriella

AU - Breen, Edmond J.

AU - Khan, Alamgir

AU - Mohamedali, Abidali

AU - Muktadir, Md Golam

AU - Ranganathan, Shoba

AU - Tan, Sock Hwee

AU - Nice, Edouard

AU - Baker, Mark S.

N1 - Copyright the Author(s) 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2015

Y1 - 2015

N2 - Background: Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 μL) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek® Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay. Results: Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research. Proseek found that expression of Carcinoembryonic Antigen (CEA), IL-8 and prolactin are significantly correlated with CRC stage. Conclusions: CEA, IL-8 and prolactin expression were found to identify between control (unaffected), non-malignant (Dukes' A + B) and malignant (Dukes' C + D) stages.

AB - Background: Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 μL) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek® Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay. Results: Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research. Proseek found that expression of Carcinoembryonic Antigen (CEA), IL-8 and prolactin are significantly correlated with CRC stage. Conclusions: CEA, IL-8 and prolactin expression were found to identify between control (unaffected), non-malignant (Dukes' A + B) and malignant (Dukes' C + D) stages.

UR - http://www.scopus.com/inward/record.url?scp=84988695346&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/nhmrc/1010303

U2 - 10.1186/s12014-015-9081-x

DO - 10.1186/s12014-015-9081-x

M3 - Article

VL - 12

SP - 1

EP - 12

JO - Clinical Proteomics

T2 - Clinical Proteomics

JF - Clinical Proteomics

SN - 1542-6416

IS - 1

M1 - 10

ER -